Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor grade, bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Stephen, O’Shaughnessy, Joyce, Martin, Miguel, Huober, Jens, Toi, Masakazu, Sohn, Joohyuk, André, Valérie A. M., Martin, Holly R., Hardebeck, Molly C., Goetz, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219718/
https://www.ncbi.nlm.nih.gov/pubmed/34158513
http://dx.doi.org/10.1038/s41523-021-00289-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219718/
https://www.ncbi.nlm.nih.gov/pubmed/34158513
http://dx.doi.org/10.1038/s41523-021-00289-7

Ejemplares similares